Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/44028
Title: Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol.
Author: Rubio Valera, Maria
Serrano Blanco, Antoni
Travé i Mercadé, Pere
Peñarrubia María, María Teresa
Ruiz, Mar
March Pujol, Marian
Keywords: Atenció farmacèutica
Atenció primària
Depressió psíquica
Anàlisi cost-benefici
Assaigs clínics
Pharmacy practice
Primary health care
Mental depression
Cost effectiveness
Clinical trials
Issue Date: 5-Aug-2009
Publisher: BioMed Central
Abstract: Background: Treatment of depression, the most prevalent and costly mental disorder, needs to be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and costeffectiveness of a community pharmacist intervention developed to improve adherence and outcomes of primary care patients with depression. Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients receiving a pharmaceutical care support programme in primary care with patients receiving usual care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked for written informed consent in order to participate in the study. Diagnosis will be confirmed using the SCID-I. The intervention consists of an educational programme focused on improving knowledge about medication, making patients aware of the importance of compliance, reducing stigma, reassuring patients about side-effects and stressing the importance of carrying out general practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main outcome measure is compliance with antidepressants. Secondary outcomes include; clinical severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D), satisfaction with the treatment received, side-effects, chronic physical conditions and sociodemographics. The use of healthcare and social care services will be assessed with an adapted version of the Client Service Receipt Inventory (CSRI). Discussion: This trial will provide valuable information for health professionals and policy makers on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the context of primary care. Trial registration: NCT00794196
Note: Reproducció del document publicat a: http://dx.doi.org/10.1186/1471-2458-9-284
It is part of: Bmc Public Health, 2009, vol. 9, num. 284
Related resource: http://dx.doi.org/10.1186/1471-2458-9-284
URI: http://hdl.handle.net/2445/44028
ISSN: 1471-2458
Appears in Collections:Articles publicats en revistes (Bioquímica i Fisiologia)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
569495.pdf225.81 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons